This paper is in the following e-collection/theme issue:

JMIR Theme Issue: COVID-19 Special Issue (2452) Theme Issue: Novel Coronavirus (COVID-19) Outbreak Rapid Reports (1517)

Published on in Vol 22, No 9 (2020): September

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/21758, first published .
Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review

Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review

Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review

Authors of this article:

Sohaib Roomi1 Author Orcid Image ;   Waqas Ullah1 Author Orcid Image ;   Faizan Ahmed1 Author Orcid Image ;   Soban Farooq2 Author Orcid Image ;   Usama Sadiq1 Author Orcid Image ;   Asad Chohan3 Author Orcid Image ;   Munnam Jafar1 Author Orcid Image ;   Maryum Saddique4 Author Orcid Image ;   Shristi Khanal1 Author Orcid Image ;   Robert Watson1 Author Orcid Image ;   Margot Boigon1 Author Orcid Image
Article Authors Cited by (14) Tweetations (8) Metrics

Journals

  1. Tleyjeh I, Kashour Z, Damlaj M, Riaz M, Tlayjeh H, Altannir M, Altannir Y, Al-Tannir M, Tleyjeh R, Hassett L, Kashour T. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clinical Microbiology and Infection 2021;27(2):215 View
  2. Hariyanto T, Hardyson W, Kurniawan A. Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis. Drug Research 2021;71(05):265 View
  3. Khan F, Stewart I, Fabbri L, Moss S, Robinson K, Smyth A, Jenkins G. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax 2021;76(9):907 View
  4. Rabow M, Wang C, Zhang S, Tahir P, Small E, Borno H. Examining reporting and representation of patients with cancer in COVID‐19 clinical trials. Cancer Reports 2021;4(4) View
  5. Puhl A, Fritch E, Lane T, Tse L, Yount B, Sacramento C, Fintelman-Rodrigues N, Tavella T, Maranhão Costa F, Weston S, Logue J, Frieman M, Premkumar L, Pearce K, Hurst B, Andrade C, Levi J, Johnson N, Kisthardt S, Scholle F, Souza T, Moorman N, Baric R, Madrid P, Ekins S. Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms. ACS Omega 2021;6(11):7454 View
  6. Rezaei S, Fatemi B, Karimi Majd Z, Minaei H, Peikanpour M, Anjidani N, Taheri A, Dastan F, Mosaed R. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis. Expert Review of Clinical Immunology 2021;17(5):499 View
  7. Wei Q, Lin H, Wei R, Chen N, He F, Zou D, Wei J. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infectious Diseases of Poverty 2021;10(1) View
  8. Conti V, Corbi G, Sellitto C, Sabbatino F, Maci C, Bertini N, De Bellis E, Iuliano A, Davinelli S, Pagliano P, Filippelli A. Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis. Journal of Personalized Medicine 2021;11(7):628 View
  9. Jiang W, Li W, Wu Q, Han Y, Zhang J, Luo T, Guo Y, Yang Y, Zhu P, Xia X. Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis. Infectious Diseases and Therapy 2021;10(3):1677 View
  10. Urbina F, Puhl A, Ekins S. Recent advances in drug repurposing using machine learning. Current Opinion in Chemical Biology 2021;65:74 View
  11. Rubio‐Rivas M, Forero C, Mora‐Luján J, Montero A, Formiga F, Homs N, Albà‐Albalate J, Sánchez L, Rello J, Corbella X. Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2021;41(11):884 View
  12. Deng J, Zhou F, Heybati K, Ali S, Zuo Q, Hou W, Dhivagaran T, Ramaraju H, Chang O, Wong C, Silver Z. Efficacy of Chloroquine and Hydroxychloroquine for the Treatment of Hospitalized COVID-19 Patients: A Meta-Analysis. Future Virology 2022;17(2):95 View
  13. Núñez-Gil I, Ayerbe L, Fernandez-Pérez C, Estrada V, Eid C, Arroyo-Espliguero R, Romero R, Becerra-Muñoz V, Uribarri A, Feltes G, Trabattoni D, Molina M, Aguado M, Pepe M, Cerrato E, Huang J, Astrua T, Alfonso E, Castro-Mejía A, Raposeiras-Roubin S, Buzón L, Paeres C, Mulet A, Lal-Trehan N, Garcia-Vazquez E, Fabregat-Andres O, Akin I, D´Ascenzo F, Gomez-Rosado P, Ugo F, Fernández-Ortiz A, Macaya C. Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; the HOPECovid- 19 Registry. Anti-Infective Agents 2023;21(2) View
  14. Chaimowicz B, Villela A, Menezes B, Coutinho C, Araujo C, Santos C, Pimenta C, Silva D, Fonseca D, Valadares N. EFICÁCIA DA CLOROQUINA E HIDROXICLOROQUINA NA PROFILAXIA E TERAPIA DA COVID-19 - UMA REVISÃO SISTEMÁTICA. REVISTA FOCO 2024;17(7):e5757 View